44th week of 2008 patent applcation highlights part 55 |
Patent application number | Title | Published |
20080269143 | Dmt-Derivative Compounds and Related Compositions and Methods of Use - The present invention relates to symmetric and asymmetric dimeric Dmt (2′,6′-ditnethyl) compounds and Dmt derivative compounds with dual δ and μ opioid receptor antagonist activity. Also, the present invention provides compositions comprising these compounds and it provides methods of using these compounds. | 2008-10-30 |
20080269144 | Synthesis of Inhibitors of P90Rsk - The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural SLO1O1-1 product and has provided access to material sufficient for detailed biological evaluation. | 2008-10-30 |
20080269145 | 18-Membered macrocycles and analogs thereof - The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically | 2008-10-30 |
20080269146 | 4''-Substituted Erythromycin Derivative - A compound of formula (I) | 2008-10-30 |
20080269147 | RNA interference mediating small RNA molecules - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 2008-10-30 |
20080269148 | Modified Small Interfering Rna Molecules and Methods of Use - The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2′-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2′-Fluorine. The invention provides that the 2′-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3′end of the molecule. | 2008-10-30 |
20080269149 | Chimeric Vectors - The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent. | 2008-10-30 |
20080269150 | Intra-vascular kidney gene therapy with plasmid encoding BMP-7 - The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention. | 2008-10-30 |
20080269151 | Fusion proteins of mycobacterium tuberculosis - The present invention relates to fusion proteins containing at least two | 2008-10-30 |
20080269152 | Nucleic acid binding oligonucleotides - The present application pertains to products and methods related to the ability of short nucleotide oligomers to bind the tertiary or globular structure of nucleic acids. This application discloses libraries of short oligomers and methods for using these libraries. | 2008-10-30 |
20080269153 | INCREASED STABILITY OF A DNA FORMULATION BY INCLUDING POLY-L-GLUTAMATE - Aspects of the present invention is related to DNA vaccine formulations having enhanced stability comprising at least one DNA plasmid capable of expressing an antigen in cells of mammal and poly-L-glutamate; wherein the DNA plasmid is present in the vaccine formulation at a concentration of at least 1 mg/ml, and the poly-L-glutamate is present in the amount of weight that is 1% of the amount of DNA plasmid. Some aspects of the present invention is related to methods of stabilizing DNA plasmid in a DNA vaccine formulation. Additionally, the present invention is related to methods for introducing a DNA vaccine formulation having enhanced stability into a cell of a selected tissue in a recipient. | 2008-10-30 |
20080269154 | Novel neurotrophic factor protein and uses thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 2008-10-30 |
20080269155 | REMEDY OR PREVENTIVE FOR KIDNEY DISEASE AND METHOD OF DIAGNOSING KIDNEY DISEASE - A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases according to the present invention comprises measuring activity or content of casein kinase 2, or measuring expression amount of casein kinase 2 gene in a sample separated from body. | 2008-10-30 |
20080269156 | Inhibitors of RTP801 and their use in disease treament - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein. | 2008-10-30 |
20080269157 | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations - Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG genes. | 2008-10-30 |
20080269158 | E2epf Ubiquitin Carrier Protein-Von Hippel-Lindau Interaction and Uses Thereof - The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF- | 2008-10-30 |
20080269159 | COMPOSITIONS AND METHODS FOR REGULATION OF SMOOTH MUSCLE CELLS AND BLOOD PRESSURE - The invention encompasses a composition for regulating smooth muscle cells. In particular, the invention encompasses a vector comprising a smooth muscle promoter operably-linked to a nucleic acid encoding a calcium-activated potassium channel. | 2008-10-30 |
20080269160 | INDUCED ACTIVATION IN DENDRITIC CELLS - The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide. | 2008-10-30 |
20080269161 | Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease - Provided is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin comprising contacting the cell with a therapeutically effective dose of an inhibitor of mitochondrial hyperpolarization. | 2008-10-30 |
20080269162 | Novel Medicaments for Anti-Retroviral Treatments - This invention relates to the use of a sulphated or phosphated polysaccharide for the preparation of a medicine for treatments against retroviruses, more particularly against lentiviruses and oncoviruses, and particularly against HIV, including strains of these retroviruses that are resistant to known anti-retroviral agents; this medicine acts on the replication cycle of said retroviruses by inhibition of their RT. | 2008-10-30 |
20080269163 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis - Described herein are methods for protecting cells from ultrasound-mediated cytolysis. | 2008-10-30 |
20080269164 | Preparation and Application of Heparin Silver - The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topic topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation. | 2008-10-30 |
20080269165 | USE OF SULFATED GLYCOSAMINOGLYCANS FOR ESTABLISHING EFFECTIVE LABOR IN WOMEN - The invention refers to the use of sulfated glycosamino-glycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women. | 2008-10-30 |
20080269166 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME - Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders. | 2008-10-30 |
20080269167 | Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s) - A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid. | 2008-10-30 |
20080269168 | WRINKLE-DIMINISHING AGENT - An antiwrinkle agent which is highly effective in alleviating wrinkles caused by the photoaging. The present invention relates to an antiwrinkle agent comprising an N-acetylglucosamine organic acid ester represented by the following general formula (1): | 2008-10-30 |
20080269169 | Camptothecin analogs and methods of preparation thereof - A method of administering a topoisomerase inhibiting agent to a mammal includes administering a pharmaceutically effective amount of a compound having the following formula or a pharmaceutically acceptable salt thereof: | 2008-10-30 |
20080269170 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors - The disclosure relates to compounds of formula (I): | 2008-10-30 |
20080269171 | FUNGICIDAL MIXTURES BASED ON PROTHIOCONAZOLE AND AN INSECTICIDE - A fungicidal mixture, comprising
| 2008-10-30 |
20080269172 | Lysine based compounds - The present invention provides lysine based compounds of the formula; | 2008-10-30 |
20080269173 | Composition for Stimulating Growth of Dermal Papilla Cells and Promoting Hair Follicle Growth Comprising Vitamin C Derivatives - Disclosed is a composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin C derivatives. | 2008-10-30 |
20080269174 | Fungicidal Combinations - A formulated mixture useful for treating plant propagation material comprising (A) Tebuconazole; and (B) one or more compounds selected from Carboxin, Chlorothalonil, Difenoconazole, Azoxystrobin, Fluquinconazole, Metalaxyl, Mefenoxam, Thiram, Abamectin, Lambda-cyhalothrin, Beta-cyflutrin, Tefluthrin, Thiamethoxam, Flubendamide and a compound of formula (A-1) and (C) one or more customary formulation adjuvants; with the proviso that the mixture excludes the mixtures consisting, as active ingredients, of (I) tebuconazole, carboxin and tridimenol and (II) tebuconazole, difenconazole and fludioxonil. | 2008-10-30 |
20080269175 | INCREASED DRUG LOADING CAPACITY OF POLYMERIC MATERIAL - A method includes (i) contacting a polymeric material with a first solvent to produce a pre-extracted polymeric material, and (ii) contacting the pre-extracted material with a solution comprising one or more therapeutic agents and a second solvent to incorporate the therapeutic agents into the pre-extracted polymeric material. The first or second solvents are the same or different. | 2008-10-30 |
20080269176 | New Salts - There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), | 2008-10-30 |
20080269177 | PESTICIDAL COMPOSITIONS - Pesticidal compositions containing a pesticidally acceptable carrier, and a synergistic blend of plant essential oils as a pesticidally active ingredient and optionally a synergist, and methods for using same, are disclosed. | 2008-10-30 |
20080269178 | Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions - The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced. | 2008-10-30 |
20080269179 | Use of Megestrol Acetate for the Treatment of Obstructive Pulmonary Diseases - The present invention relates to the treatment of patients suffering from pulmonary diseases, in particular from chronic obstructive pulmonary disease (COPD), bronchial asthma, cystic fibrosis and chronic cough in particular as caused by ACE-Inhibitors using megestrol acetate. | 2008-10-30 |
20080269180 | Androgen Treatment in Females - A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months. | 2008-10-30 |
20080269181 | METHODS FOR TREATING A POSTERIOR SEGMENT OF AN EYE - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time. | 2008-10-30 |
20080269182 | Method of treating cancers with SAHA and Pemetrexed - The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic. | 2008-10-30 |
20080269183 | Novel Therapy for Treatment of Chronic Degenerative Brain Diseases and Nervous System Injury - In one aspect the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition. | 2008-10-30 |
20080269184 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof - A niosome having a metalloporphyrin complex embedded therein comprising a cationized metalloporphyrin complex and a niosome-forming substance. The niosome having a metalloporphyrin complex embedded therein has an SOD activity, can interact with superoxide anionic radicals (O | 2008-10-30 |
20080269185 | Methods Of Treating Oral Mucositis - Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation. | 2008-10-30 |
20080269186 | Functional Nanomaterials With Antibacterial and Antiviral Activity - The present invention relates to nanomaterials comprised of metal oxides associated with cationic metals having antibacterial activity. In particular, the present invention relates to nanocrystalline compounds of formula (I): AOx- (L-Men+) i, (I) where AOx represents the metal oxide or metalloid oxide, with x=1 or 2; Me11“1” is a metal ion having antibacterial activity, with n=1 or 2; L is a bifunctional molecule, either organic or organometallic, capable of binding simultaneously with the metal oxide or metalloid oxide and the metal ion Men+; and i represents the number of L-Men+groups bound to a AOx nanoparticle. | 2008-10-30 |
20080269187 | Methods for Treatment and Prevention of Otitis Media Using Chemical Penetration Enhancers to Facilitate Transmembrane Drug Delivery Into the Middle Ear - Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a chemical penetration enhancer, such as propylene glycol. The compositions are applied to the ear so as to contact the outer surface of an intact tympanic membrane to deliver the medicament across the membrane and into the middle ear. The medicaments delivered according to the methods of the invention include antibiotic, anti-viral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae. | 2008-10-30 |
20080269188 | Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy - The present invention relates to a method for determining variable response to statin therapy in patients afflicted with or susceptible to develop cardiovascular diseases, hypercholesterolemia, Diabetes and metabolic disorders involving high baseline plasma lipid level such as high LDL-C level, comprising detecting the presence or absence of the Pro 155T hr (C463A) variant in the Organic Anion Transporting Polypeptide-C(OATP-C) gene, wherein the presence of said variant is indicative of superior response to statin therapy. It also concerns tailored treatment of different populations of patients according to the Pro155Thr (C463A) variant genotype. | 2008-10-30 |
20080269189 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer - Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided. | 2008-10-30 |
20080269190 | Quaternary ammonium compounds useful as muscarinic receptor antagonists - The invention provides compounds of the formula: | 2008-10-30 |
20080269191 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 2008-10-30 |
20080269192 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 2008-10-30 |
20080269193 | Tetrahydroindole and Tetrahydroindazole Derivatives - The invention provides indole and indazole compounds of Formula (I) | 2008-10-30 |
20080269194 | Compositions And Methods Relating To Novel Compounds And Targets Thereof - The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, vascular abnormalities, and the like. | 2008-10-30 |
20080269195 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine - Compounds of formula (I) or a salt thereof are disclosed: | 2008-10-30 |
20080269196 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists - The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. | 2008-10-30 |
20080269197 | AROMATIC SULFONES AND THEIR MEDICAL USE - The invention provides compounds of formula (I): | 2008-10-30 |
20080269198 | PHARMACEUTICAL COMPOSITIONS OF ESTROGENIC AGENTS - This invention relates to novel pharmaceutical carrier or excipient systems and oral pharmaceutical compositions comprising 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof. | 2008-10-30 |
20080269199 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR - The invention concerns a compound of formula (I): | 2008-10-30 |
20080269200 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors - Indole carboxamide compounds of Formula (I): | 2008-10-30 |
20080269201 | Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments - The present invention relates to Azepane- or Azocane-substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals | 2008-10-30 |
20080269202 | Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents - Disclosed are novel 2,3-benzodiazepine derivatives and methods of making the same. | 2008-10-30 |
20080269203 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF - The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like. | 2008-10-30 |
20080269204 | Compounds and Methods of Use Thereof - Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof. | 2008-10-30 |
20080269205 | METHODS TO PREVENT VERTICAL TRANSMISSION OF INFECTIOUS DISEASES - The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B | 2008-10-30 |
20080269206 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 2008-10-30 |
20080269207 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS - The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. | 2008-10-30 |
20080269208 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders - There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof: | 2008-10-30 |
20080269209 | Pyrazoloisoquinoline Derivatives - New compounds of formula I, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors. (I) | 2008-10-30 |
20080269210 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 2008-10-30 |
20080269211 | Indazole Derivatives - This invention relates to compounds of the formula (I): | 2008-10-30 |
20080269212 | Amino acid derivatives of indolinone based protein kinase inhibitors - Amino acid derivatives of pyrrolyl-indolinones and their amide or ester derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 2008-10-30 |
20080269213 | 8-Hydroxyquinoline compounds and methods thereof - The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof. | 2008-10-30 |
20080269214 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors - Compounds of formula (I) and their pharmaceutically acceptable salts are described: Formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. | 2008-10-30 |
20080269215 | Bisamide Inhibitors of Hedgehog Signaling - The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 2008-10-30 |
20080269216 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders - The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I | 2008-10-30 |
20080269217 | Melanocortin-4 receptor binding compounds and methods of use thereof - Provided are MC4-R binding compounds of the formula XVII: | 2008-10-30 |
20080269218 | Novel Hsp90 Inhibitor - Disclosed is a triazole derivative represented by the general formula (1) below or a pharmacologically acceptable salt thereof. Also disclosed are a prodrug of such a triazole derivative and an HSP90 inhibitor containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group or the like; Y represents a mercapto group, a hydroxyl group, an optionally substituted sulfonyl group, an optionally substituted amino group or the like; and R represents an optionally substituted aryl or amino group or the like.) | 2008-10-30 |
20080269219 | Neurotrophin production/secretion promoting agent - A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula: | 2008-10-30 |
20080269220 | Aminophenylpropanoic Acid Derivative - A compound represented by the formula (1): | 2008-10-30 |
20080269221 | ANTIBACTERIAL AGENTS - Antibacterial compounds of formula I are provided: | 2008-10-30 |
20080269222 | Use of Delmopinol in the Treatment of Acne - The present invention relates to the use of a morpholino compound having the general formula: (I) wherein R | 2008-10-30 |
20080269223 | Mouth Dissolvable and Meltable, and Water Dispersable Delivery Formulation - A mouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, disintegrating agent is crosslinked polyvinyl pyrrolidone and binder is maltodextrin. This system optionally comprises one or more of other excipients selected from the group comprising lubricants, sweetners and flavouring agent. | 2008-10-30 |
20080269224 | Substituted Triazines as Prion Protein Ligands and Their Use to Detect or Remove Prions - Compounds of formula (I) wherein R | 2008-10-30 |
20080269225 | Prokineticin 1 receptor antagonists - The present invention relates to certain novel compounds of Formula (I): | 2008-10-30 |
20080269226 | Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors - The present invention relates to methods of preserving renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 2008-10-30 |
20080269227 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors - The present invention is related to fused pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2008-10-30 |
20080269228 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. | 2008-10-30 |
20080269229 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2008-10-30 |
20080269230 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders - This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment of alleviation of diseases or disorders associated with, or mediated by a drop in extra cellular pH. | 2008-10-30 |
20080269231 | Phenazine Compounds and Use Thereof in Autoimmune and Inflammatory Disease - The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases such as those caused by arthritis and rheumatoid arthritis. | 2008-10-30 |
20080269232 | Pyridazinyl Amine Derivatives, the Use Thereof in the Preparation of Picorna Virus Inhibitors - The present invention relates to substituted pyridazinylamine derivatives of the formula I or pharmaceutically acceptable salts or hydrates thereof, wherein the substituents are defined as in the description, their preparation process, pharmaceutical compositions comprising them, and uses of the said compounds as picorna virus inhibitors for prevention and/or treatment of diseases caused by picorna viruses. | 2008-10-30 |
20080269233 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds - The present invention relates to a class of compounds of general formula (I) | 2008-10-30 |
20080269234 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed. | 2008-10-30 |
20080269235 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS - New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4. | 2008-10-30 |
20080269236 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof - The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof. | 2008-10-30 |
20080269237 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS - This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: | 2008-10-30 |
20080269238 | Thiazolopyrimidine Derivative - The present invention provides a compound represented by the following Formula: | 2008-10-30 |
20080269239 | Pyrimidine Compounds as Histamine Modulators - The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds. | 2008-10-30 |
20080269240 | Novel Adenine Compound - An adenine compound useful as a medicine represented by the following formula (1): | 2008-10-30 |
20080269241 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S - Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis. | 2008-10-30 |
20080269242 | Crystalline Salts of 7-[4-(4-Naphthalen-1-Yl-Piperazin-1-Yl)-Butoxy]-3,4-Dihydro-1H-[1,8]Naphthyridine-2-One - The present application relates to crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-di-hydro-1H-[1,8]naphthyridin-2-one, process for preparation of the crystalline salts, pharmaceutical compositions containing the crystalline salts, and use of the crystalline salts for treating certain disorders or conditions. | 2008-10-30 |